Mark G. Kris, MD, discusses what is most important in treating patients with lung cancer today.
Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses what is most important in treating patients with lung cancer today.
First, Kris says that at every decision point, physicians should look at all therapeutic options for each individual illness and patient. By not looking at these individual variations, patients are not receiving the more effective therapy that could be better for that individual person.
Kris also notes that a multiple modality concept should be used at this point in time as well. More options are available than before, such as surgery, ablation, or stereotactic body radiation therapy (SBRT). Physicians should not simply be switching to different chemotherapy, EGFR agents, or tyrosine kinase inhibitors (TKIs).
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
March 25th 2024During a Case-Based Roundtable® event, Christine, Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non–small cell lung cancer in the first article of a 2-part series.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More